BACKGROUND: Primary pulmonary non-Hodgkin lymphoma (NHL) is a rare entity. Despite its favorable prognosis, an optimal treatment approach has not been established until today, as there are few debated heterogeneous data in the literature. Many therapeutic options such as surgery, radiotherapy, chemotherapy alone or in combination, immunotherapy and/or immunochemotherapy all with similar results, have been reported. CASE DESCRIPTION: We report the case of a 68-year-old man diagnosed with a primary marginal zone B-cell pulmonary NHL, with a durable complete response to rituximab monotherapy. CONCLUSION: We support the therapeutic application of rituximab monotherapy as an attractive option for this malignancy. This effective approach exhibits significant antitumor activity leading to long-term complete remission and minimal hematological toxicity in contrast to other intensive chemotherapies and/or radiotherapy, which might have serious side effects. HIPPOKRATIA 2017, 21(2): 108-110.
BACKGROUND:Primary pulmonary non-Hodgkin lymphoma (NHL) is a rare entity. Despite its favorable prognosis, an optimal treatment approach has not been established until today, as there are few debated heterogeneous data in the literature. Many therapeutic options such as surgery, radiotherapy, chemotherapy alone or in combination, immunotherapy and/or immunochemotherapy all with similar results, have been reported. CASE DESCRIPTION: We report the case of a 68-year-old man diagnosed with a primary marginal zone B-cell pulmonary NHL, with a durable complete response to rituximab monotherapy. CONCLUSION: We support the therapeutic application of rituximab monotherapy as an attractive option for this malignancy. This effective approach exhibits significant antitumor activity leading to long-term complete remission and minimal hematological toxicity in contrast to other intensive chemotherapies and/or radiotherapy, which might have serious side effects. HIPPOKRATIA 2017, 21(2): 108-110.
Authors: Shahid Ahmed; Steven J Kussick; Anita K Siddiqui; Tawfiqul A Bhuiya; Arfa Khan; Stephen Sarewitz; Harry Steinberg; Cristina P Sison; Kanti R Rai Journal: Eur J Cancer Date: 2004-06 Impact factor: 9.162
Authors: Jung Han Kim; Se-Hoon Lee; Jinny Park; Ho Young Kim; Soon Il Lee; Joon-Oh Park; Kihyun Kim; Won Seog Kim; Chul Won Jung; Young Suk Park; Young-Hyuck Im; Won Ki Kang; Mark H Lee; Keunchil Park; Joung Ho Han; Young Hyeh Ko Journal: Jpn J Clin Oncol Date: 2004-09 Impact factor: 3.019
Authors: R Borie; M Wislez; G Thabut; M Antoine; A Rabbat; L-J Couderc; I Monnet; H Nunes; F-X Blanc; H Mal; A Bergeron; D Dusser; D Israël-Biet; B Crestani; J Cadranel Journal: Eur Respir J Date: 2009-06-18 Impact factor: 16.671
Authors: Antonio Salar; Eva Domingo-Domenech; Carlos Panizo; Concepción Nicolás; Joan Bargay; Ana Muntañola; Miguel Canales; José Luis Bello; Juan Manuel Sancho; José Francisco Tomás; María José Rodríguez; Javier Peñalver; Carlos Grande; José Javier Sánchez-Blanco; Luis Palomera; Reyes Arranz; Eulogio Conde; Mar García; Juan Fernando García; Dolores Caballero; Carlos Montalbán Journal: Blood Date: 2017-08-11 Impact factor: 22.113